Piper Sandler Remains a Buy on Ionis Pharmaceuticals (IONS)

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $63.00. The company’s shares closed yesterday at $41.84.

According to TipRanks, Bratzel is a 2-star analyst with an average return of 0.0% and a 42.22% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Akebia Therapeutics, and Codexis.

Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $58.69.

Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $324.51 million and a GAAP net loss of $9.26 million. In comparison, last year the company earned a revenue of $151.89 million and had a GAAP net loss of $52.43 million

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals (IONS) Company Description:

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.